Dentsply Sirona Reports Third Quarter 2026 Results
Key Highlights
- ➤Q3 net sales $836 million, down 7.6% year over year
- ➤Adjusted EPS $0.29, down 29.4% year over year
- ➤FY2026 outlook targets approximately $3.5 billion sales and $1.20-$1.30 adjusted EPS
- ➤Wellspect Healthcare sales rose 10.1% as reported to a quarterly record
- ➤Free cash flow fell to $0 million from $40 million year over year
Expert Statements
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
“We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions”
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
“We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network.”
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
“Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth.”
News Summary * Q3 2026 net sales of $836 million * Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01) * Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29 * Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™ portfolio with the launch of the Surity™ Urinary Management System * Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.
"We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth."
Get started
Create a free account to read the full story.